STERIS plc (NYSE:STE - Get Free Report) Director Mohsen Sohi sold 4,893 shares of the firm's stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $253.22, for a total value of $1,239,005.46. Following the completion of the sale, the director owned 24,305 shares of the company's stock, valued at approximately $6,154,512.10. This trade represents a 16.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
STERIS Stock Down 1.1%
Shares of NYSE STE opened at $253.50 on Friday. The firm's 50-day simple moving average is $222.55 and its 200 day simple moving average is $224.61. The company has a market cap of $24.62 billion, a price-to-earnings ratio of 30.07 and a beta of 0.86. The company has a quick ratio of 1.44, a current ratio of 2.05 and a debt-to-equity ratio of 0.23. STERIS plc has a 12-month low of $195.14 and a 12-month high of $269.44.
STERIS (NYSE:STE - Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The medical equipment provider reported $2.94 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.26. The firm had revenue of $1.59 billion during the quarter, compared to analysts' expectations of $1.56 billion. STERIS had a net margin of 13.41% and a return on equity of 14.80%. The company's quarterly revenue was up 8.8% compared to the same quarter last year. During the same quarter last year, the company posted $2.47 EPS. On average, research analysts expect that STERIS plc will post 11.46 earnings per share for the current fiscal year.
STERIS Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Thursday, December 17th. Stockholders of record on Tuesday, November 17th will be paid a dividend of $0.69 per share. This represents a $2.76 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend is Tuesday, November 17th. STERIS's dividend payout ratio is 32.74%.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in the business. Benjamin Edwards Inc. boosted its stake in shares of STERIS by 28.1% in the 3rd quarter. Benjamin Edwards Inc. now owns 144,857 shares of the medical equipment provider's stock valued at $30,428,000 after purchasing an additional 31,789 shares during the last quarter. First Trust Advisors LP grew its position in shares of STERIS by 2.7% during the 3rd quarter. First Trust Advisors LP now owns 251,561 shares of the medical equipment provider's stock worth $52,830,000 after buying an additional 6,530 shares during the period. Advisors Asset Management Inc. bought a new stake in shares of STERIS during the third quarter worth approximately $820,000. Private Wealth Asset Management LLC bought a new stake in shares of STERIS during the third quarter worth approximately $234,000. Finally, Private Advisor Group LLC acquired a new position in STERIS in the third quarter valued at approximately $212,000. 94.69% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several research firms recently weighed in on STE. Wall Street Zen cut shares of STERIS from a "strong-buy" rating to a "buy" rating in a research report on Sunday, October 11th. KeyCorp upped their price objective on STERIS from $269.00 to $284.00 and gave the stock an "overweight" rating in a report on Friday, November 6th. Piper Sandler reiterated an "overweight" rating and issued a $275.00 price objective (up from $270.00) on shares of STERIS in a research report on Friday, August 7th. Morgan Stanley raised STERIS from an "overweight" rating to a "buy" rating in a research note on Friday. Finally, Weiss Ratings upgraded STERIS from a "hold (c)" rating to a "hold (c+)" rating in a research report on Monday. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $276.33.
Get Our Latest Analysis on STERIS
STERIS Company Profile
(
Get Free Report)
STERIS plc (NYSE: STE) provides infection prevention and procedural products and services for healthcare, pharmaceutical, research, and other industries. Its offerings include sterilizers, washers and other equipment used to clean and sterilize medical devices and surgical instruments, as well as products for operating rooms and endoscopy procedures. The company also provides equipment installation, maintenance, repair, and training, along with contract sterilization and laboratory testing services.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
